BioAge Labs
said on Friday it is discontinuing its mid-stage trial studying its experimental drug as a monotherapy and in combination with Eli Lilly’s tirzepatide for the treatment of obesity.
The drug developer decided to stop the trial after
liver transaminitis
, or high levels of certain liver enzymes, were observed in patients receiving the experimental drug, azelaprag.
Tirzepatide is the active ingredient in Lilly’s diabetes drug Mounjaro and weight-loss treatment Zepbound.
The mid-stage trial enrolled about 220 individuals with obesity aged 55 years and older.
I’m Manas Ranjan Sahoo: Founder of “Webtirety Software”. I’m a Full-time Software Professional and an aspiring entrepreneur, dedicated to growing this platform as large as possible. I love to Write Blogs on Software, Mobile applications, Web Technology, eCommerce, SEO, and about My experience with Life.
